Novo Nordisk Just Bet $812M That Obesity's Future Isn't GLP-1
Novo Nordisk just dropped $812 million on a tiny AI-driven startup to find obesity drugs that have nothing to do with GLP-1. The deal with Deep Apple Therapeutics signals that even the king of Ozempic and Wegovy thinks the next era of weight loss will look very different.
The Biggest Name in Weight Loss Is Looking Elsewhere
Novo Nordisk built an empire on GLP-1 drugs. Ozempic and Wegovy became household names, the kind of medications your uncle asks about at Thanksgiving. So it's worth paying attention when the company quietly signals that GLP-1s alone won't be enough.
This week, Novo signed an $812 million deal with Deep Apple Therapeutics, a San Francisco startup most people have never heard of. The goal: discover oral small-molecule drugs that target a completely different biological pathway for obesity. Not GLP-1. Not GIP. Not any incretin at all.
That's like McDonald's investing nearly a billion dollars into a restaurant concept that doesn't serve burgers.
Who Is Deep Apple, and Why Does Novo Care?
Deep Apple launched in late 2023 with $52 million in Series A funding from Apple Tree Partners, a life sciences venture firm. The company was built around three academic co-founders from Stanford and UCSF, each bringing a specific superpower to the table.
Georgios Skiniotis (Stanford) is a world leader in cryo-EM, a technique that lets scientists take molecular-level snapshots of proteins in different shapes. Brian Shoichet (UCSF) pioneered virtual screening, essentially letting computers test billions of potential drug molecules without touching a single test tube. And John Irwin (UCSF) created the ZINC database, a library of tens of billions of synthesizable compounds.
Put those three capabilities together and you get Deep Apple's pitch: use AI and structural biology to find drug-like molecules that fit into protein pockets traditional methods would miss entirely. The company claims it can go from picking a target to optimizing a lead compound in under 12 months, which is roughly four times faster than industry norms.
Deep Apple already has seven programs across inflammatory, immunological, weight-loss, and endocrine diseases. Two of them (an MRGPRX2 antagonist and a GIPR antagonist) are approaching the stage where they'd need to start the studies required before testing in humans.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Inside the Deal
The structure is straightforward. Deep Apple handles the discovery work, using its AI platform to find and optimize compounds against a novel non-incretin GPCR target (a type of cell-surface receptor that's different from the ones GLP-1 drugs activate). Once candidates are ready for the final preclinical push, Novo takes over.
Novo gets exclusive worldwide rights to develop, manufacture, and sell whatever comes out of the collaboration, across all diseases. Deep Apple gets up to $812 million in milestone payments, plus royalties on any eventual sales.
For Deep Apple, the math is compelling. One analyst-style estimate pegged the company's risk-adjusted present value from this deal at roughly $197 million, about four times its Series A. Not bad for a company that's barely two and a half years old.
Why Novo Is Playing Defense by Going on Offense
To understand why this deal matters, you need to understand the pressure Novo is under. Eli Lilly's tirzepatide (sold as Zepbound for obesity) is eating into Novo's market share. Lilly also has retatrutide, a triple-acting drug that hits GLP-1, GIP, and glucagon receptors simultaneously, showing strong weight-loss data in late-stage trials. And Lilly is pushing eloralintide, an amylin receptor agonist headed for Phase 3, giving it a credible non-GLP-1 play as well.
The obesity market is fragmenting. It's no longer a one-drug-class story. Amylin analogs, triple agonists, oral small molecules: the next cycle will look very different from the current GLP-1-dominated landscape. Novo can't afford to be a one-trick pony, even if that trick generated tens of billions in revenue.
To its credit, Novo has been on a shopping spree. The Deep Apple partnership is just one piece of a broader diversification blitz. In 2025 alone, Novo signed a $2.2 billion deal with Septerna for oral small-molecule cardiometabolic therapies (including a triple agonist), a $550 million collaboration with Replicate Bioscience for self-replicating RNA approaches to obesity, and a partnership with Vivtex worth up to $2.1 billion for oral drug delivery technology in early 2026.
Novo has been committing billions in potential deal value to pipeline diversification through a wave of recent partnerships.
The Non-Incretin Frontier
The specific GPCR target in the Deep Apple deal hasn't been publicly disclosed, which makes it impossible to evaluate the biology directly. But the broader landscape of non-incretin GPCR targets for obesity is surprisingly rich.
Researchers are exploring the neurokinin-2 receptor (NK2R), which showed sustained weight loss in rodent studies published in Nature in 2024. The melanocortin-4 receptor (MC4R) is already validated in rare genetic obesity, though broader use has been limited by cardiovascular side effects. The ghrelin receptor (the "hunger hormone" pathway) is another target, along with several metabolite-sensing receptors like GPR40, GPR120, and GPR119.
The point is that GPCRs represent a massive, underexplored frontier for obesity drugs. About a third of all approved medications target GPCRs, yet most obesity GPCRs remain untouched by modern drug design. Deep Apple's platform was built specifically to crack these targets open.
Wall Street Shrugged (for Now)
The institutional reaction to the deal was, in a word, muted. Novo's stock barely moved on the news. Most analysts characterized it as a small, option-like R&D bet in the context of Novo's enormous market cap. The collaboration is discovery-stage, meaning it won't contribute to earnings for years and carries high binary risk.
Retail investors were more enthusiastic. Stocktwits sentiment on Novo shifted from neutral to bullish within 24 hours, with message volume spiking from low to high.
The disconnect makes sense. Professional investors are trained to discount early-stage programs heavily; the probability that any discovery collaboration produces a marketed drug is low. But the strategic signal is what matters here. Novo is telling the market it won't ride semaglutide into the sunset. It's building for a post-GLP-1 world, even while GLP-1s are still printing money.
The Bigger Picture
New CEO M. Doustdar has been ruthless about focusing Novo's pipeline. The company dropped a CB1 receptor program, abandoned a duplicative GLP-1/GIP co-agonist, ended its cell therapy partnership with Heartseed, and cut roughly 9,000 employees to save about 8 billion DKK per year. The message is clear: fewer bets, higher conviction.
The assets that survived the cull tell you where Novo is headed. CagriSema (semaglutide plus cagrilintide, an amylin analog) delivered 23% weight loss in trials and has been submitted for US approval. Amycretin/zenagamtide, a GLP-1/amylin co-agonist, showed up to 24.3% weight loss in early studies and is entering Phase 3 in both injectable and oral forms.
Deep Apple's non-incretin program sits further out on the risk curve, but it fills a gap none of Novo's other assets cover. If it works, Novo would have an oral pill for obesity that doesn't touch the incretin pathway at all, something no one has today.
That's worth an $812 million lottery ticket. Especially when the alternative is watching the competition build the future without you.
Deals & M&A5 min read
Incyte Just Spent $1.25 Billion on a Disease Most People Haven't Heard Of
Incyte is paying $1.25 billion upfront (up to $2 billion total) for Vega Therapeutics and its Phase 3 von Willebrand disease drug. It's a massive bet on a bleeding disorder most people can't name, and Wall Street is cautiously on board.
